NASDAQ:CYTK

Cytokinetics Stock Forecast, Price & News

$29.04
+0.93 (+3.31 %)
(As of 07/28/2021 03:59 PM ET)
Add
Compare
Today's Range
$27.95
$29.32
50-Day Range
$18.54
$30.10
52-Week Range
$14.71
$31.41
Volume50,315 shs
Average Volume1.31 million shs
Market Capitalization$2.08 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.38
30 days | 90 days | 365 days | Advanced Chart
Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.


Cytokinetics logo

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

677th out of 2,210 stocks

Pharmaceutical Preparations Industry

346th out of 867 stocks

Analyst Opinion: 4.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

Is Cytokinetics a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cytokinetics stock.
View analyst ratings for Cytokinetics
or view top-rated stocks.

What stocks does MarketBeat like better than Cytokinetics?

Wall Street analysts have given Cytokinetics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cytokinetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Cytokinetics
.

How can I listen to Cytokinetics' earnings call?

Cytokinetics will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "7387377".

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The biopharmaceutical company had revenue of $6.55 million for the quarter, compared to the consensus estimate of $7.83 million. Cytokinetics had a negative trailing twelve-month return on equity of 213.63% and a negative net margin of 230.55%.
View Cytokinetics' earnings history
.

How has Cytokinetics' stock been impacted by COVID-19?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CYTK shares have increased by 141.4% and is now trading at $29.04.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CYTK?

11 brokerages have issued 12-month target prices for Cytokinetics' stock. Their forecasts range from $16.00 to $54.00. On average, they anticipate Cytokinetics' share price to reach $42.36 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price.
View analysts' price targets for Cytokinetics
or view top-rated stocks among Wall Street analysts.

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 57, Pay $1.02M)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 58, Pay $605.85k)
  • Mr. David W. Cragg, Chief HR & Admin. Officer (Age 65, Pay $541.12k)
  • Mr. Mark A. Schlossberg, Sr. VP of Legal, Gen. Counsel & Sec. (Age 60, Pay $625.06k)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 57, Pay $691.06k)
  • Dr. James A. Spudich, Co-Founder & Member of Scientific Advisory Board (Age 79)
  • Mr. Robert Wong, VP & Chief Accounting Officer (Age 54)
  • Ms. Diane Weiser, Sr. VP of Corp. Communications & Investor Relations
  • Ms. Bonnie A. Charpentier, Sr. VP of Regulatory Affairs & Compliance (Age 69)
  • Mr. Scott R. Jordan, Sr. VP of Global Marketing & Commercial Strategy

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics CEO Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among Cytokinetics' employees.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.07%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Ching Jaw, David Cragg, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics
.

Which major investors are buying Cytokinetics stock?

CYTK stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics
or or view top insider-buying stocks.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $29.04.

How much money does Cytokinetics make?

Cytokinetics has a market capitalization of $2.08 billion and generates $55.83 million in revenue each year. The biopharmaceutical company earns $-127,290,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

How many employees does Cytokinetics have?

Cytokinetics employs 184 workers across the globe.

When was Cytokinetics founded?

Cytokinetics was founded in 1997.

What is Cytokinetics' official website?

The official website for Cytokinetics is www.cytokinetics.com.

Where are Cytokinetics' headquarters?

Cytokinetics is headquartered at 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.